Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207483 | 0.84 | NR4A2 (0.37) | NR4A2DYRK1AF7F3PIK3CG | |
| SCHEMBL5748176 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL3389355 | 0.76 | ALDH1A1 (0.50) | PDGFRBPDGFRAALDH1A1KDM4EMEN1 | |
| SCHEMBL209087 | 0.76 | HTT (0.50) | DYRK1AALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL693644 | 0.75 | PDGFRB (0.35) | PDGFRBPDGFRADYRK1A | |
| SCHEMBL5748301 | 0.73 | HPGDS (0.38) | ALDH1A1KDM4ECYP2A6 | |
| SCHEMBL695179 | 0.72 | BACE1 (0.42) | PDGFRBPDGFRADYRK1A | |
| SCHEMBL16289398 | 0.72 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL2894578 | 0.72 | EGFR (0.53) | PDGFRBPDGFRAALDH1A1KDM4EMEN1 | |
| SCHEMBL207977 | 0.72 | TYMS (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111094233-B | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-03-15 | — | — | CN | claimed |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-05-20 | — | — | US | claimed |
| EP-3665156-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-06-17 | — | — | EP | claimed |
| CN-111094233-A | Compounds, compositions and methods | 戴纳立制药公司 | 2020-05-01 | — | — | CN | claimed |
| WO-2019032743-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-02-14 | — | — | WO | claimed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | claimed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | claimed |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-28 | — | — | US | claimed |
| EP-2160187-B1 | SPIROINDALONES | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | claimed |
| US-8445477-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-21 | — | — | US | claimed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | claimed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | claimed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | claimed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | claimed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | claimed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | claimed |
| EP-0667850-B1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE FARMACEUTICI SPA (IT) | 1997-05-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | NR4A2 3125/4885PDGFRB 3607/4885PDGFRA 3407/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | NR4A2 3125/4885PDGFRB 3607/4885PDGFRA 3407/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | NR4A2 3125/4885PDGFRB 3607/4885PDGFRA 3407/4885 |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | NR4A2 4177/4885PDGFRB 1055/4885PDGFRA 751/4885 |
| US-20210147435-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | NR4A2 2920/4885PDGFRB 1598/4885PDGFRA 3158/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | NR4A2 1317/4885PDGFRB 3355/4885PDGFRA 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.